Henderson D M, Sifri C D, Rodgers M, Wirth D F, Hendrickson N, Ullman B
Department of Biochemistry and Molecular Biology, Oregon Health Sciences University, Portland 97201-3098.
Mol Cell Biol. 1992 Jun;12(6):2855-65. doi: 10.1128/mcb.12.6.2855-2865.1992.
Drug resistance is a major impediment to the effective treatment of parasitic diseases. The role of multidrug resistance (mdr) genes and their products in this drug resistance phenomenon, however, remains controversial. In order to determine whether mdr gene amplification and overexpression can be connected to a multidrug resistance phenotype in parasitic protozoa, a mutant strain of Leishmania donovani was generated by virtue of its ability to proliferate in medium containing increasing concentrations of vinblastine. The vinblastine-resistant strain, VINB1000, displayed a cross-resistance to puromycin and the anthracyclines, a growth phenotype that could be attributed to an impaired ability to accumulate the toxic drugs. By using the polymerase chain reaction, two different DNA fragments, LEMDR06 and LEMDRF2, were amplified from leishmanial genomic DNA, and each amplified fragment encoded a product that was significantly homologous to parts of the mammalian P-glycoprotein. In the VINB1000 strain, the mdr gene recognized by the LEMDR06 probe was amplified approximately 50-fold in copy number, whereas the mdr genes that hybridized to LEMDRF2 or to a fragment of the previously characterized ltpgpA gene were not amplified. Moreover, the VINB1000 cell line expressed a LEMDR06 gene transcript of 12.5 kb in size that was not detected in the parental wild-type strain. To furnish a functional test for mdr gene amplification and expression in L. donovani, the L. donovani gene recognized by the LEMDR06 polymerase chain reaction product, ldmdr1, was isolated from a genomic library, transfected into wild-type cells, and amplified over 500-fold by selection in 0.5 mg of G418 per ml. The resulting transfectants were resistant to all drugs to which VINB1000 cells were resistant and sensitive to all drugs to which VINB1000 cells were sensitive. These studies demonstrate that amplification of the ldmdr1 gene either by direct selection or subsequent to transfection can confer a drug-resistant phenotype in parasitic protozoa similar to that observed for MDR mammalian cells.
耐药性是有效治疗寄生虫病的主要障碍。然而,多药耐药(mdr)基因及其产物在这种耐药现象中的作用仍存在争议。为了确定mdr基因扩增和过表达是否与寄生原生动物的多药耐药表型相关,利用杜氏利什曼原虫在含有浓度不断增加的长春碱的培养基中增殖的能力,构建了一个突变株。长春碱耐药株VINB1000对嘌呤霉素和蒽环类药物表现出交叉耐药性,这种生长表型可归因于积累有毒药物的能力受损。通过聚合酶链反应,从利什曼原虫基因组DNA中扩增出两个不同的DNA片段LEMDR06和LEMDRF2,每个扩增片段编码的产物与哺乳动物P-糖蛋白的部分区域具有显著同源性。在VINB1000株中,LEMDR06探针识别的mdr基因拷贝数扩增了约50倍,而与LEMDRF2或先前鉴定的ltpgpA基因片段杂交的mdr基因未扩增。此外,VINB1000细胞系表达了一个大小为12.5 kb的LEMDR06基因转录本,而在亲本野生型菌株中未检测到。为了对杜氏利什曼原虫中mdr基因的扩增和表达进行功能测试, 从基因组文库中分离出LEMDR06聚合酶链反应产物识别的杜氏利什曼原虫基因ldmdr1,转染到野生型细胞中,并通过在每毫升含0.5 mg G418的培养基中筛选使其扩增了500多倍。所得转染子对VINB1000细胞耐药的所有药物均耐药,对VINB1000细胞敏感的所有药物均敏感。这些研究表明,通过直接选择或转染后扩增ldmdr1基因可使寄生原生动物产生耐药表型,类似于在多药耐药哺乳动物细胞中观察到的表型。